ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,256Medicare Part D Prescriptions Filled, Including Refills

Rank: 80 out of 337

$352K Total Retail Price of All Prescriptions

Rank: 133 out of 337

433 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
26% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 433 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

11% of this provider’s 433 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

2% of this provider’s 8,067 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

13% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$38 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
PRAVASTATIN SODIUM 550 496 1 14
OMEPRAZOLE 395 318 2 4
LEVOTHYROXINE SODIUM 368 319 3 5
LISINOPRIL 354 312 4 2
AMLODIPINE BESYLATE 332 292 5 3
ATENOLOL 255 248 6 10
METOPROLOL TARTRATE 251 224 7 6
FUROSEMIDE 213 201 8 8
CITALOPRAM HBR 210 209 9 17
HYDROCHLOROTHIAZIDE 203 188 10 9
LOSARTAN POTASSIUM 200 196 11 15
FLUTICASONE PROPIONATE 189 164 12 34
LISINOPRIL-HYDROCHLOROTHIAZIDE 189 180 12 31
HYDROCODONE-ACETAMINOPHEN 178 153 S3 14 13
SERTRALINE HCL 162 137 15 18
METFORMIN HCL 151 127 16 12
LOSARTAN-HYDROCHLOROTHIAZIDE 150 139 17 60
SIMVASTATIN 148 141 18 1
ATORVASTATIN CALCIUM 147 120 19 7
WARFARIN SODIUM 113 107 20 11
RANITIDINE HCL 109 88 21 30
ALPRAZOLAM 106 98 22 78
FELODIPINE ER 103 102 23 79
ZOLPIDEM TARTRATE 101 82 24 23
METOPROLOL SUCCINATE 97 84 25 21
QUINAPRIL HCL 97 95 25 50
ALENDRONATE SODIUM 96 95 27 19
TAMSULOSIN HCL 95 82 28 25
GLYBURIDE-METFORMIN HCL 86 76 R 29 99
ENALAPRIL MALEATE 84 76 30 37
AZITHROMYCIN 75 66 31 51
GLYBURIDE 71 62 R 32 53
GABAPENTIN 69 47 33 20
PAROXETINE HCL 69 69 33 46
TRAZODONE HCL 68 60 35 16
LEVOXYL 65 50 36 90
POLYETHYLENE GLYCOL 3350 61 52 37 47
DONEPEZIL HCL 56 56 38 22
DOXAZOSIN MESYLATE 54 54 39 68
ALLOPURINOL 53 41 40 28
PROAIR HFA 50 33 41 38
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 11, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.